The Medicines Safety Improvement Programme (MedSIP) aims to reduce severe avoidable medication-related harm by 50% by 2024. This is in line with the third WHO Global Patient Safety Challenge: Medication Without Harm.
The main focus of the programme this coming year relates to Improving chronic non-cancer pain management by reducing high-risk opioid prescribing.
In support of this, we are:
Our learning from this work will be shared both across the region via the community of practice and also link into existing networks working in this area such as Medicines Safety leads, medicines optimisation groups and the Safety Improvement network (once established).
who we are working with